Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cadila, Holtzman Invest In Rwanda

by Lisa M. Jarvis
March 14, 2011 | A version of this story appeared in Volume 89, Issue 11

Cadila Pharmaceuticals of Ahmedabad, India, and U.S.-based Holtzman Group have formed a pharmaceutical manufacturing joint venture called CSM GlobalPharma. The venture, in partnership with investment fund Crystal Ventures, Rwanda’s Social Security Fund, and the drug purchasing nonprofit Camerwa, will invest more than $65 million to build a drug manufacturing facility in Kigali, Rwanda. The project will progress in four phases: production of solids, tablets, and capsules; manufacture of liquids, gels, ointments, creams, and syrups; preparation of biologicals, injectables, and vaccines; and synthesis of active pharmaceutical ingredients. Manufacturing is expected to start up in 2013.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.